☆ 4.6 Editorial Material

Rectal Carcinoma on 68Ga-PSMA PET/CT

CLINICAL NUCLEAR MEDICINE (2016)

Journal

CLINICAL NUCLEAR MEDICINE

Volume 41, Issue 3, Pages E167-E168

Publisher

LIPPINCOTT WILLIAMS & WILKINS

DOI: 10.1097/RLU.0000000000001072

Keywords

prostate-specific membrane antigen; rectal; PET/CT; PET

Categories

Radiology, Nuclear Medicine & Medical Imaging

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

We report on a case of biopsy-proven and MRI-staged rectal carcinoma with avid prostate-specific membrane antigen (prostate-specific membrane antigen(HBED)) uptake on Ga-68 PET/CT as part of the workup for synchronous prostate cancer. This case adds to the growing number of observational reports on the presence of significant nonprostatic prostate-specific membrane antigen activity in malignant tumors and highlights the need for careful interpretation of unsuspected sites.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Radiology, Nuclear Medicine & Medical Imaging

Determination of optimal 68 Ga-PSMA PET/CT imaging time in prostate cancers by total-body dynamic PET/CT

Jun Wen, Yinjie Zhu, Lianghua Li, Jianjun Liu, Yumei Chen, Ruohua Chen

Summary: Dynamic total-body PET imaging in patients with prostate cancer showed that 6 minutes post-injection was the optimal time for imaging, avoiding interference from bladder activity and detecting lesions with relatively low PSMA uptake. Additionally, imaging at 35-59 minutes post-injection could also yield similar results to imaging at 60 minutes post-injection.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

18F-DCFPyL PET/CT for Initially Diagnosed and Biochemically Recurrent Prostate Cancer: Prospective Trial with Pathologic Confirmation

Gary A. Ulaner, Beth Thomsen, Jeffrey Bassett, Robert Torrey, Craig Cox, Kevin Lin, Trushar Patel, Tust Techasith, Audrey Mauguen, Steven P. Rowe, Liza Lindenberg, Esther Mena, Peter Choyke, Jeffrey Yoshida

Summary: The positive predictive value (PPV) of DCFPyL PET/CT was evaluated for suspected distant metastases and recurrence sites in newly diagnosed high-risk and biochemically recurrent (BCR) prostate cancer. The results showed a PPV of 74% in newly diagnosed prostate cancer and 89% in BCR prostate cancer. However, false-positive findings in ribs and pelvic bones should be considered.

RADIOLOGY (2022)

Add to Collection

Review Radiology, Nuclear Medicine & Medical Imaging

Role of 18F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Management of Oligometastatic Prostate Cancer: AJR Expert Panel Narrative Review

Bital Savir-Baruch, Peter L. Choyke, Steven P. Rowe, David M. Schuster, Rathan M. Subramaniam, Hossein Jadvar

Summary: Oligometastatic disease is considered an intermediary clinical state with unique implications for cancer treatment; New-generation imaging methods, such as PSMA PET/CT, can identify disease sites in oligometastatic prostate cancer earlier; PSMA PET/CT is likely to become the preferred imaging modality after regulatory approval, driving the development of new treatment approaches.

AMERICAN JOURNAL OF ROENTGENOLOGY (2021)

Add to Collection

Article Oncology

Meta-analysis of (18) F-PSMA-1007 PET/CT, (18) F-FDG PET/CT, and Ga-68-PSMA PET/CT in diagnostic efficacy of prostate Cancer

Wenxiao Yu, Ming Zhao, Yingjun Deng, Shengjing Liu, Guanchao Du, Bin Yan, Ziwei Zhao, Ning Sun, Jun Guo

Summary: This study compared the diagnostic value of (18) F-PSMA-1007 PET/CT, (18) F-FDG PET/CT, and Ga-68-PSMA PET/CT in prostate cancer. The results showed that both (18) F-PSMA-1007 PET/CT and Ga-68 PSMA PET/CT demonstrated higher diagnostic efficacy compared to (18) F-FDG PET/CT.

CANCER IMAGING (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancer

Rie von Eyben, Manuela Andrea Hoffmann, Cigdem Soydal, Irene Virgolini, Murat Tuncel, Mathieu Gauthe, Daniel S. Kapp, Finn Edler von Eyben

Summary: A biochemical recurrence (BCR) risk model was created based on pretest prostate specific antigen (PSA) and restaging prostate specific membrane antigen (PSMA) PET/CT. Both pretest PSA and PSMA PET/CT were found to be important for the overall survival (OS) of BCR patients. Treatment center, International Society of Urologic Pathology (ISUP) grade, pretest PSA threshold, and the grouping of positive sites on the restaging PSMA PET/CT were significant predictors of OS.

BIOMEDICINES (2023)

Add to Collection

Review Radiology, Nuclear Medicine & Medical Imaging

The Detection Performance of F-18-Prostate-Specific Membrane Antigen-1007 PET/CT in Primary Prostate Cancer A Systemic Review and Meta-analysis

Ya-Ting Huang, Neng-Chuan Tseng, Yen-Kung Chen, Kuo-How Huang, Hsiu-Ying Lin, Ya-Yao Huang, Thomas I. S. Hwang, Yen-Chuan Ou

Summary: In this study, we conducted a systematic review and meta-analysis to evaluate the detection performance of F-18-PSMA-1007 PET/CT in patients with primary prostate cancer. The results showed excellent performance of F-18-PSMA-1007 in detecting localized prostatic tumor lesions and regional lymph node metastasis.

CLINICAL NUCLEAR MEDICINE (2022)

Add to Collection

Review Radiology, Nuclear Medicine & Medical Imaging

Comparing the Detection Performance Between Multiparametric Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen PET/CT in Patients With Localized Prostate Cancer A Systematic Review and Meta-analysis

Yuh-Feng Wang, Chun-Yu Lo, Li-Yu Chen, Chi-Wei Chang, Ya-Ting Huang, Ya-Yao Huang, Yi-Hsiu Huang

Summary: This meta-analysis compared the diagnostic performance of PSMA PET and mpMRI in detecting and T staging localized prostatic tumors, and found that F-18-DCFPyL PET was superior to mpMRI in detecting localized prostatic tumors, while the detection performance of PSMA PET for localized prostatic tumors and T staging was comparable to that of mpMRI.

CLINICAL NUCLEAR MEDICINE (2023)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

The PRIMARY Score: Using Intraprostatic 68Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis

Louise Emmett, Nathan Papa, James Buteau, Bao Ho, Victor Liu, Matthew Roberts, James Thompson, Dan Moon, Gemma Sheehan-Dare, Omar Alghazo, Shikha Agrawal, Declan Murphy, Phillip Stricker, Thomas A. Hope, Michael S. Hofman

Summary: This study analyzed the clinical significance of Ga-68-PSMA PET/CT in a low-prevalence population and proposed a 5-point PRIMARY score to improve the accuracy of diagnosing csPCa. The results showed that the PRIMARY score had high sensitivity and specificity in distinguishing high-risk and low-risk patterns.

JOURNAL OF NUCLEAR MEDICINE (2022)

Add to Collection

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

Hepatic Small Vessel Neoplasm Mimics Prostate Cancer on F-18-DCFPyl PET/CT

Keith L. Spinali, David J. Papke, Hina J. Shah

Summary: F-18-DCFPyl is used to detect recurrent or metastatic prostate cancer and can target nonprostatic disease entities that mimic prostate cancer. The interpreting physician needs to consider serum prostate-specific antigen levels and uptake distribution to avoid misdiagnosis of metastatic prostate cancer. We describe the association of F-18-DCFPyl uptake with a previously undescribed hepatic small vessel neoplasm.

CLINICAL NUCLEAR MEDICINE (2023)

Add to Collection

Article Health Care Sciences & Services

Very Low Prostate PET/CT PSMA Uptake May Be Misleading in Staging Radical Prostatectomy Candidates

Barak Rosenzweig, Rennen Haramaty, Tima Davidson, Alon Lazarovich, Asaf Shvero, Miki Haifler, Jonathan Gal, Shay Golan, Sagi Shpitzer, Azik Hoffman, Omri Nativ, Yuval Freifeld, Rani Zreik, Zohar A. Dotan

Summary: This study evaluated a unique subpopulation of RP candidates with negative PSMA PET/CT scans and found that misleading results can occur. However, the study also discovered a correlation between PSMA uptake and disease aggressiveness.

JOURNAL OF PERSONALIZED MEDICINE (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Head-to-Head Comparison of 68Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10-Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients

Melline G. M. Schilham, Patrik Zamecnik, Bastiaan M. Prive, Bas Israel, Mark Rijpkema, Tom Scheenen, Jelle O. Barentsz, James Nagarajah, Martin Gotthardt

Summary: Accurate assessment of lymph node metastases in prostate cancer patients is crucial. PSMA PET/CT and nano-MRI are imaging modalities with high potential for identifying LN metastases. This study compared the results of these modalities, finding that nano-MRI detected more suspicious LNs, especially smaller ones, across all anatomical regions of the pelvis. It suggests that nano-MRI could complement PSMA PET/CT in imaging PCa patients, but further investigation is needed.

JOURNAL OF NUCLEAR MEDICINE (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Diagnostic accuracy of [18F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer

Clemens Mingels, Karl Peter Bohn, Axel Rominger, Ali Afshar-Oromieh, Ian Alberts

Summary: This study investigated the diagnostic accuracy of [F-18]PSMA-1007 PET/CT in biochemically recurrent prostate cancer. The results showed good performance in terms of regional sensitivity and negative predictive value, but limited positive predictive value, especially for bone lesions.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Diagnostic Performance of 68Ga Prostate-specific Membrane Antigen PET/MRI Compared with Multiparametric MRI for Detecting Clinically Significant Prostate Cancer

David Margel, Hanna Bernstine, David Groshar, Yaara Ber, Orian Nezrit, Niv Segal, Maxim Yakimov, Jack Baniel, Liran Domachevsky

Summary: Gallium 68 prostate-specific membrane antigen PET/MRI demonstrated improved specificity for detecting clinically significant prostate cancer compared to multiparametric MRI, especially in Prostate Imaging Reporting and Data System grade 3 lesions.

RADIOLOGY (2021)

Add to Collection

Review Urology & Nephrology

The Role of PSMA PET/CT and PET/MRI in the Initial Staging of Prostate Cancer

Vishnu Murthy, Ida Sonni, Namasvi Jariwala, Roxanna Juarez, Robert E. Reiter, Steven S. Raman, Thomas A. Hope

Summary: PSMA PET imaging shows promising performance in the initial staging of prostate cancer, with high sensitivity and specificity for detecting tumors and guiding treatment options. Further research is needed to evaluate its role in management changes and treatment of metastatic disease.

EUROPEAN UROLOGY FOCUS (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Detection efficacy of [89Zr]Zr-PSMA-617 PET/CT in [68Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer

Florian Rosar, Fadi Khreish, Robert J. Marlowe, Andrea Schaefer-Schuler, Caroline Burgard, Stephan Maus, Sven Petto, Mark Bartholomae, Samer Ezziddin

Summary: Preliminary data suggest that using Zr-89-labeled PSMA ligand radiotracers may be more effective than using tracers with short-lived radionuclides in detecting suspicious lesions in patients with biochemical recurrence of prostate cancer. In this study, 78% of patients had suspicious lesions detected on 24-h and 48-h scans, with higher detection rates on the 48-h scans. This suggests that imaging at a later time may be preferable.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2023)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer

Matthew J. Roberts, Andrew Morton, Peter Donato, Samuel Kyle, David A. Pattison, Paul Thomas, Geoff Coughlin, Rachel Esler, Nigel Dunglison, Robert A. Gardiner, Suhail A. Doi, Louise Emmett, John Yaxley

Summary: Intraprostatic (68)Ga-PSMA-11 intensity is prognostic and may be a valuable new biomarker in localised prostate cancer, especially in men with biopsy-proven Gleason 3 + 4 disease considering an initial approach of active surveillance or focal therapy.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

Add to Collection

Correction Radiology, Nuclear Medicine & Medical Imaging

68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer (Jul, 10.1007/s00259-020-04944-2, 2020)

Matthew J. Roberts, Andrew Morton, Peter Donato, Samuel Kyle, David A. Pattison, Paul Thomas, Geoff Coughlin, Rachel Esler, Nigel Dunglison, Robert A. Gardiner, Suhail A. Doi, Louise Emmett, John Yaxley

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

Add to Collection

Article Oncology

A prospective study investigating the efficacy and toxicity of definitive ChemoRadiation and ImmunOtherapy (CRIO) in locally and/or regionally advanced unresectable cutaneous squamous cell carcinoma

Charles Lin, Trishna Ballah, Michelle Nottage, Karen Hay, Benjamin Chua, Lizbeth Kenny, Paul Thomas, Michele Teng, Jacqui Keller, Trang Le, Jennifer Edmunds, Brett Hughes

Summary: This study aims to investigate the efficacy of combining curative intent chemoradiation with the PD-L1 inhibitor durvalumab for patients with unresectable advanced cSCC, focusing on complete response rate and treatment safety.

RADIATION ONCOLOGY (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Preclinical Molecular PET-CT Imaging Targeting CDCP1 in Colorectal Cancer

Tahleesa J. Cuda, Yaowu He, Thomas Kryza, Tashbib Khan, Brian W. Tse, Kamil A. Sokolowski, Cheng Liu, Nicholas Lyons, Madeline Gough, Cameron E. Snell, David K. Wyld, Stephen Rose, Andrew D. Riddell, Andrew R. L. Stevenson, Paul A. Thomas, David A. Clark, Simon Puttick, John D. Hooper

Summary: Colorectal cancer is a common malignancy, with molecular imaging potentially used to detect and characterize tumors. CDCP1 protein expression is elevated in CRC, making it a potential target for molecular imaging.

CONTRAST MEDIA & MOLECULAR IMAGING (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation

Evyn G. Arnfield, Paul A. Thomas, Matthew J. Roberts, Anita M. Pelecanos, Stuart C. Ramsay, Charles Y. Lin, Melissa J. Latter, Peter L. Garcia, David A. Pattison

Summary: The study found that [F-18]PSMA-1007 avid NSBLs rarely indicate prostate cancer bone metastases. NSBLs with SUVmax < 7.2 were classified as likely benign, while those with SUVmax 7.2-11.1 may be classified as equivocal or metastatic based on patient clinical risk factors, scan appearance, and potential management implications. An SUVmax threshold of >= 7.2 was found to maximize the Youden's index in distinguishing between NSBLs and definite prostate cancer bone metastases.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68 Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer

David A. Pattison, Maciej Debowski, Brook Gulhane, Evyn G. Arnfield, Anita M. Pelecanos, Peter L. Garcia, Melissa J. Latter, Charles Y. Lin, Matthew J. Roberts, Stuart C. Ramsay, Paul A. Thomas

Summary: This study aimed to compare the concordance of [F-18]PSMA-1007 and [(68)Ga]Ga-PSMA-11 in TNM diagnosis and tracer uptake. The results showed differences in tracer uptake in most physiological sites, but high consistency in overall AJCC prognostic stage.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

Add to Collection

Editorial Material Urology & Nephrology

The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study

Louise Emmett, James Buteau, Nathan Papa, Daniel Moon, James Thompson, Matthew J. Roberts, Kris Rasiah, David A. Pattison, John Yaxley, Paul Thomas, Anthony C. Hutton, Shikha Agrawal, Amer Amin, Alexandar Blazevski, Venu Chalasani, Bao Ho, Andrew Nguyen, Victor Liu, Jonathan Lee, Gemma Sheehan-Dare, Raji Kooner, Geoff Coughlin, Lyn Chan, Thomas Cusick, Benjamin Namdarian, Jada Kapoor, Omar Alghazo, Henry H. Woo, Nathan Lawrentschuk, Declan Murphy, Michael S. Hofman, Phillip Stricker

Summary: The combination of PSMA + MRI shows higher negative predictive value and sensitivity for detecting clinically significant prostate cancer compared to MRI alone, but with a lower specificity. Combined PSMA + MRI may help avoid unnecessary prostate biopsies in some men.

EUROPEAN UROLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Positron emission tomography and magnetic resonance imaging in experimental human malaria to identify organ-specific changes in morphology and glucose metabolism: A prospective cohort study

John Woodford, Ashley Gillman, Peter Jenvey, Jennie Roberts, Stephen Woolley, Bridget E. Barber, Melissa Fernandez, Stephen Rose, Paul Thomas, Nicholas M. Anstey, James S. McCarthy

Summary: PET/MRI imaging revealed that early P. vivax infection has a greater impact on the spleen compared to P. falciparum, with no significant changes in bone marrow or liver. This study suggests potential differences in organ tropism and metabolic activity between the two malaria species.

PLOS MEDICINE (2021)

Add to Collection

Review Urology & Nephrology

Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review

Stephen McGeorge, Michael Kwok, Andrew Jiang, Louise Emmett, David A. Pattison, Paul A. Thomas, John W. Yaxley, Matthew J. Roberts

Summary: PSMA PET is more accurate than conventional imaging for staging of intermediate- or high-risk prostate cancer, but some primary tumors have low PSMA ligand uptake. FDG PET can be used to further define disease extent in early-stage castrate-resistant PCa and may be beneficial for more accurate staging. Further studies are needed to determine the additive benefit of FDG PET and its potential indication for prognosis.

ADVANCES IN UROLOGY (2021)

Add to Collection

Letter Biophysics

[F-18]GE-180 PET/CT assessment of enterocytic translocator protein (TSPO) over-expression: a pilot study in gastrointestinal GVHD

Ashleigh P. Scott, Paul Thomas, David A. Pattison, Leo Francis, Paula Ridge, Siok-Keen Tey, Glen A. Kennedy

BONE MARROW TRANSPLANTATION (2022)

Add to Collection

Correction Radiology, Nuclear Medicine & Medical Imaging

Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68 Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer (Aug, 10.1007/s00259-021-05520-y, 2021)

David A. Pattison, Maciej Debowski, Brook Gulhane, Evyn G. Arnfield, Anita M. Pelecanos, Peter L. Garcia, Melissa J. Latter, Charles Y. Lin, Matthew J. Roberts, Stuart C. Ramsay, Paul A. Thomas

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

Add to Collection

Article Oncology

The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison

Arsalan Tariq, Michael Kwok, Adam Pearce, Handoo Rhee, Samuel Kyle, Phillip Marsh, Sheliyan Raveenthiran, David Wong, Rhiannon McBean, Jurjen Westera, Nigel Dunglison, Rachel Esler, Anojan Navaratnam, John W. Yaxley, Paul Thomas, David A. Pattison, Matthew J. Roberts

Summary: This study compared the use of FDG and PSMA PET/CT with SOC imaging for the characterization, staging, and restaging of RCC. The results showed that dual tracer PET/CT was mostly concordant in the assessment of primary and metastatic RCC. PET imaging outperformed conventional imaging in the evaluation of metastatic disease.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Risk of metastatic disease using [F-18]PSMA-1007 PET/CT for primary prostate cancer staging

Venkata Avinash Chikatamarla, Satomi Okano, Peter Jenvey, Alexander Ansaldo, Matthew J. Roberts, Stuart C. Ramsay, Paul A. Thomas, David A. Pattison

Summary: PSMA-1007 PET/CT provides accurate prostate cancer imaging and demonstrates an association between ISUP grade and PSA level with metastatic disease. The study found that higher PSA levels and ISUP grades are associated with improved specificity and sensitivity for detecting metastatic disease.

EJNMMI RESEARCH (2021)

Add to Collection

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

Potential Pitfall in the Interpretation of Ganglioneuronal Uptake of 18F-PSMA-1007 PET/CT Scans Performed With a High Spatial Resolution Digital PET Scanner

Nadya Kisiel, Paul Thomas

Summary: This case study highlights the importance of caution when interpreting PET/CT scans performed on high-resolution digital scanners to avoid mistaking ganglia uptake for metastatic disease.

CLINICAL NUCLEAR MEDICINE (2022)

Add to Collection

Article Neuroimaging

Reduced cortical cholinergic innervation measured using [18F]-FEOBV PET imaging correlates with cognitive decline in mild cognitive impairment

Ying Xia, Eamonn Eeles, Jurgen Fripp, Donna Pinsker, Paul Thomas, Melissa Latter, Vincent Dore, Amir Fazlollahi, Pierrick Bourgeat, Victor L. Villemagne, Elizabeth J. Coulson, Stephen Rose

Summary: The dysfunction of the cholinergic basal forebrain neurotransmitter system has been found to play an important role in cognitive decline and dementia. A study used a validated method to directly measure cholinergic terminal integrity and investigated its value for assessing cholinergic denervation in the cortex and associated cognitive deficits. The results showed that there was a significant global reduction of cholinergic terminal integrity in the cortex of participants with mild cognitive impairment compared to cognitively unimpaired controls. The study also found correlations between the cholinergic terminal integrity and brain volumes, but no association with amyloid-beta status. The findings suggest the potential of using this method for early detection of cholinergic dysfunction in dementia.

NEUROIMAGE-CLINICAL (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.